Patients with advanced urothelial cancer who develop skin reactions while taking enfortumab vedotin may have better survival outcomes, according to a report from Medical Dialogues. The findings, published in JAMA, suggest that these side effects could serve as a positive prognostic marker.
Medical Dialogues reported that the study linked enfortumab vedotin–related skin toxicities to improved survival in this patient group. The antibody-drug conjugate is used to treat advanced forms of urothelial cancer, which affects the bladder and other parts of the urinary tract.
The report, which drew on research highlighted by JAMA, indicates that skin reactions—while uncomfortable—may reflect a stronger therapeutic response. This aligns with observations in other cancer treatments where certain side effects correlate with efficacy. EMJ and Medscape also covered the findings, with Medscape noting that these skin reactions appear to affect survival outcomes.
The mechanism behind this link is not fully detailed in the available reporting. However, the pattern suggests that the drug's activity in the skin may parallel its anti-tumor effects. For clinicians, this could mean that managing—rather than immediately stopping—these reactions might be worth considering, though treatment decisions should always follow established guidelines.
What to watch next: Whether future studies will confirm these skin toxicities as a reliable biomarker for guiding enfortumab vedotin dosing or duration in advanced urothelial cancer.
